


#### Outline

- 1. Why IMRT for HN cancer
- Immbolization
- **Tissue segmentation** 3.
- Treatment planning
- Plan evaluation 5.
- 6. Summary




# Why IMRT for HN Cancer Miles et al. Radiother Oncol. 2005;77(3):421-426.

- Complex anatomical region
  - Normal tissues and targets in close proximity
- Inadequate 3D planning techniques
  - No way to deliver concave dose distributions Kuppersmith et al. Ear Nose Throat J. 1999;78(4):238,241-246. Pacholke et al. Am J Clin Oncol. 2005;28(4):351-358.
- Absence of organ motion

# Complex Anatomical Region Martinez-Monge et al. Radiology. 1999;211:815-828.

- Optic nerves, chiasm, eyes, lenses
- Spinal cord, brainstem
- Parotid glands
- Oral cavity
- Temporal lobes
- Mandible, TMJ
- Larynx, ...





#### **Absence of Organ Motion**

- Little or no intrafraction organ motion
- Inter-fraction setup uncertainty can be controlled with usual intervention





#### **Indications and Contra-Indications**

- Cooperative patients
  No claustrophobia, resting tremors, etc.
- Reduce normal tissue complications
   Conformal avoidance
- To escalate dose
  - Improve local-regional control
- Avoid unwanted field junctions

### **HN Immbolization**

- GTV and CTV can be very different structures
- Maximize reproducibility
  - Head
  - Chin
  - Mandible
  - Oral cavityClavicals
    - Supraclavicular nodes



#### Immbolization Options ("Active")



#### **Immbolization Options** ("Passive")

- Masking system with Accuform custom neck mold
- Patient comfort and immbolization go hand-in-hand



#### Immbolization Options ("Passive")



### **Expected Reproducibility**

- Locate isocenter in head or upper neck
- Generally, setup error within 3 mm can be achieved
  - 1 2 mm in the head and neck
  - 2 3 mm in the shoulder region
     Tsai et al. Int J Radiat Oncol Biol Phys. 1999;43(2):455-467.
- However, some variability can be expected
   Treatment plans should account for those effects Hong et al. Int J Radiat Oncol Biol Phys. 1005;61(3):779-788.

## **Aspects of Imaging**

- Target volumes
- Normal tissues
- Image fusion

## Target Volume Delineation ICRU 50

#### Example for NPC


- GTV
  - Gross tumor on MRI and PE
- CTV
  - GTV + margin including, nasopharynx, retropharyngeal nodes, clivus, skull base, inferior sphenoid sinus, pterygoid fossae, parapharyngeal space, posterior nasal cavity and maxillary sinuses

#### • PTV


• CTV + 3-5 mm

### **Consistent with ICRU Definitions**

- GTV-T, GTV-N
- CTV-T, CTV-N1, CTV-N2, etc.




## CT Anatomy – Head/Neck



Location of inferior brainstem and superior spinal cord

# CT Anatomy – Neck




Spinal canal vs

Spinal cord

Use PRV (ICRU-62) for margin around spinal cord


# CT Anatomy – Neck





# **CT/MR Anatomy**





#### **Multi-modality Image Fusion**

- Participate in process before imaging takes place
  - Ensure same position
  - Understand setup/imaging limitations
- Talk with physician about site of interest
  Location, pre- or post-op, etc.
- Communicate uncertainty of manually fused images

## **Before Planning Begins**

- Is IMRT appropriate for this case?
- Where is the target?
- What are target doses & acceptable normal tissue doses?
  - What can be compromised?
- What is the plan?
  - Simultaneous integrated boost versus sequential cone down plans?

### **IMRT Planning**

- Same primary target as with 3DCRT
- Regional therapy requires specific identification of nodes
- Simultaneous boost
  - Lower regional dose per fraction (e.g. GTV to 66Gy and nodes to 54Gy both in 30 fractions)
- Sequential boost
  - Same dose per fraction for GTV and nodes
  - Requires two plans

#### **Physician Communication**

(managing expectations)

- Isodose lines are not as smooth as 3DCRT
  - Increases dose heterogeneity, which may affect toxicity, tumor control probability
- You can not specify an isodose line to move by millimeters
  - IMRT planning is not like changing a block edge
- Hot/cold spot will fall within the target(s)

#### **Issues with IMRT Treatments**

- Time consuming planning process and quality assurance procedures
- Many factors in plan evaluation of uncertain significance
- Exchanges exposure of larger volumes of normal tissue to low doses for smaller volumes exposed to high doses

#### **Tissue Inhomogeneity Corrections**

- AAPM Report No. 85: Tissue Inhomogeneity Corrections for Megavoltage Photon Beams
- 4 10% error in relative e<sup>-</sup> density results in ~2% error in dose
- CT Streak artifacts can be locally significant
  Do not normalize a plan to a point in this region
  - Little effect on DVH of large structures

#### **Know Published Dose Limits**

(understand what your physician will accept)

Tissue	Maximal Dose <sup>*</sup> (Gy)	Mean Dose (Gy)	Reference
Brain	60	-	Emami et al 1991
Brainstem	54	-	Emami et al 1991
Optic chiasm/nerves	54	-	Emami et al 1991
Retina	45	-	Emami et al 1991
Lens	12	-	Emami et al 1991
Parotid	70	26	Eisbruch et al 2003
Larynx	70	$\leq 25 - 30$	Stanford
Mandible	65	≤ 35 – 45	Stanford
Spinal cord	45	-	Emami et al 1991


\*Recommend lowering these dose limits by 10% when concurrent chemotherapy is used.

#### **IMRT Planning Parameters**

- Dose/volume constraints
- Number of beams
- Beam orientation / Table angles
- Tuning structures
- Collimator angle
- Isocenter placement
- Beamlet size / Intensity levels
- Direct modification of intensity maps


#### Number of Beams

- More beams = Better plan ?
- Generally Yes
  - But improvement can be marginal over 7 beams
  - Degree of improvement depends on tumor shape and proximity to critical structures




#### **Beam Orientation**


- Coplanar vs Non-coplanar
  - Ease of setup
  - Ease of planning
  - Speed of treatment
- Equi-spaced vs Selected angles
   Entrance through table/immobilization device




## **Collimator Orientation**



## **Collimator Orientation**




No collimator angle




Leaf travel direction perpendicular to the brainstem/spinal cord


# **Tuning Structure**


- A structure added just for the purpose of treatment planning
- Provides additional control over the dose distribution in IMRT plans
- Reduce normal tissue dose
- Reduce/Increase target dose




# **Tuning Structure**










#### **Isocenter Placement**

#### Issues

- Sometimes a better plan be achieved by selective isocenter placement
  - Center of GTV vs center of all targets
- Dosimetry and/or QA
- Patient setup
  - Isocenter in region of reliable bony anatomy


# **Isocenter Placement**




Choose a reliable anatomical reference point

#### **Modification of Intensity Map**


#### An option provided by some planning systems



#### **Modification of Intensity Map**



#### **Modification of Intensity Map**





## HN IMRT with Sclav Nodes


- Treating nodes in IMRT
  - Eliminates junction issues
  - Requires extra care to immobolize shoulders
  - Do not treat the supraclav nodes through the shoulders
- Treating nodes with AP field
  - Requires a method to match the IMRT fields
  - Not advised for node positive cases
  - If possible, include SCV field in IMRT optimization

# **IMRT Including Sclav Nodes**


- Tissue depth in BEV can change with shoulder position
- Unnecessary dose to the shoulders








# <section-header><section-header><section-header><section-header><section-header><section-header><section-header><text>





#### **Final Comments on Planning**

- Beam energy
  - Higher energy PA beam can help to cover Sclav nodes and reduce posterior hot spots
- Skin dose
  - Immbolization masking systems can act as a bolus to produce a severe skin reaction
- Opposed beam are "ok"

#### When The Plan is Finished


- Review the plan with your physician!
- Talk through the plan with the physician
  - What is good and bad about this plan?
  - Why did you use those beam angles?
  - Why underdose parts of the target?
  - Why can't you spare more normal tissue?
- Intrude on the physician's decision making process

#### **About Plan Evaluation**

- Maximal point doses may exceed normal tissue tolerance
- Review the DVH
  - Determine how much of the critical structure volume receives a dose that exceeds the specified limit
  - In many cases, it only correlates to a few voxels and may be acceptable

#### **About Plan Evaluation**

- Hot and cold spots must be identified using the isodose curves on a sliceby-slice basis
- The decision on hot spots should be individualized based on other clinical considerations
  - Previous treatments the region
  - Medical co-morbidities and the use of concurrent chemotherapy



## **Parting Thoughts**

- The risk of secondary malignancies is not zero
  Relative to co-morbidity and the patient's life style
- Setup uncertainty changes the position and magnitude of hot spots
- Recurrences are mainly in the high-dose regions
- Refinements and new techniques in the IMRT technique are ongoing
- Real-time adaptive IMRT based-on tumor changes is still in the future